Saudi FDA Wants Device & Drug Firms To Report Payments To Doctors, Health Institutions
The Saudi Food and Drug Authority has finalized the details of a new transparency initiative under which medical device and pharmaceutical companies will have to disclose their financial relationships with health-care professionals and institutions.
You may also be interested in...
Europe recently saw a wave of disclosures published by pharmaceutical trade associations revealing the transfers of value made by companies to health-care professionals and organizations. In this article, attorneys at the law firm Baker & McKenzie – Julie Yeni, Julia Gillert, Chloe Cornet and Elina Angeloudi – discuss how the growing trend toward imposing greater transparency in the relationships between the health industry and health-care professionals continues, and what it will mean for the medical device sector in different countries across Europe and in Saudi Arabia.
CMS releases data on $3.5 billion worth of payments made by drug and device companies to physicians and teaching hospitals in the last five months of 2013; an additional 199,000 payment records were not disclosed.
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.